Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Injury ; 46(7): 1333-40, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25956674

RESUMO

BACKGROUND AND OBJECTIVES: Whether cigarette smoking can increase the risk of hip fracture in women is unclear. This meta-analysis, which pooled results from 10 prospective cohort studies, was performed to derive a more precise estimation between cigarette smoking and the risk of hip fracture in women. MATERIALS AND METHODS: Pubmed, Cochrane Central Register of Controlled Trials and ISI Web of Science were systematically searched to identify relevant studies. A meta-analysis was performed to examine the association among 10 studies. The pooled risk estimates were calculated by using both random- and fixed-effects model. Heterogeneity among articles and their publications bias were also tested. All of the statistical analyses were performed using the software programs STATA (version 12.0). RESULTS: Relative risk was significantly increased in current female smokers (pooled RR, 1.30; 95%CI, 1.16-1.45). The association was significant among the high-dose smokers (more than 15 cigarettes per day) while not among the low-does smokers (less than 15 cigarettes per day). Omission of any single study had little effect on the pooled risk estimate. Former smokers had a similar RR of hip fracture (RR, 1.02; 95%CI, 0.93-1.11) to published papers. Smoking cessation for ≥10 years leads to a significant decline in risk. CONCLUSIONS: Smoking is associated with an increased hip fracture risk in women. Cessation of smoking for ≥10 years had a decreased impact on risk of hip fracture. Given the inconsistency among the studies in the choice of adjustments, the associations between cigarette smoking and risk of hip fracture in women await further investigation.


Assuntos
Fraturas do Quadril/etiologia , Osteoporose/etiologia , Fumar/efeitos adversos , China/epidemiologia , Estudos Transversais , Feminino , Fraturas do Quadril/epidemiologia , Fraturas do Quadril/prevenção & controle , Humanos , Osteoporose/sangue , Osteoporose/epidemiologia , Estudos Prospectivos , Fatores de Risco , Fumar/sangue , Fumar/epidemiologia , Prevenção do Hábito de Fumar , Vitamina D/sangue
2.
Biol Trace Elem Res ; 152(2): 292-6, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23334864

RESUMO

Iron overload has recently been connected with bone mineral density in osteoporosis. However, to date, the effect of iron overload on osteoblasts remains poorly understood. The purpose of this study is to examine osteoblast biological activity under iron overload. The osteoblast cells (hFOB1.19) were cultured in a medium supplemented with different concentrations (50, 100, and 200 µM) of ferric ammonium citrate as a donor of ferric ion. Intracellular iron was measured with a confocal laser scanning microscope. Reactive oxygen species (ROS) were detected by 2,7-dichlorofluorescin diacetate fluorophotometry. Osteoblast biological activities were evaluated by measuring the activity of alkaline phosphatase (ALP) and mineralization function. Results indicated that iron overload could consequently increase intracellular iron concentration and intracellular ROS levels in a concentration-dependent manner. Additionally, ALP activity was suppressed, and a decline in the number of mineralized nodules was observed in in vitro cultured osteoblast cells. According to these results, it seems that iron overload probably inhibits osteoblast function through higher oxidative stress following increased intracellular iron concentrations.


Assuntos
Sobrecarga de Ferro/metabolismo , Ferro/toxicidade , Osteoblastos/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo , Linhagem Celular , Humanos , Sobrecarga de Ferro/fisiopatologia , Osteoblastos/efeitos dos fármacos
3.
Biol Trace Elem Res ; 150(1-3): 487-95, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23054865

RESUMO

Bone metabolism has a close relationship with iron homeostasis. To examine the effects of iron excess and iron deficiency on the biological activities of osteoblast in vitro, human osteoblast cells (hFOB1.19) were incubated in a medium supplemented with 0-200 µmol/L ferric ammonium citrate and 0-20 µmol/L deferoxamine. The intracellular iron was measured by a confocal laser scanning microscope. Proliferation of osteoblasts was evaluated by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. Apoptotic cells were detected using annexin intervention V/PI staining with a flow cytometry. Alkaline phosphatase (ALP) activity was measured using an ALP assay kit. The number of calcified nodules and mineral area was evaluated by von Kossa staining assay. The expressions of type I collagen and osteocalcin of cultured osteoblasts were detected by reverse transcriptase polymerase chain reaction and Western blot. Intracellular reactive oxygen species (ROS) was measured using the oxidation-sensitive dye 2,7-dichlorofluorescin diacetate by flow cytometry. The results indicated that excessive iron inhibited osteoblast activity in a concentration-dependent manner. Low iron concentrations, in contrast, produced a biphasic manner on osteoblasts: mild low iron promoted osteoblast activity, but serious low iron inhibited osteoblast activity. Osteogenesis was optimal in certain iron concentrations. The mechanism underlying biological activity invoked by excessive iron may be attributed to increased intracellular ROS levels.


Assuntos
Anemia Ferropriva/metabolismo , Sobrecarga de Ferro/metabolismo , Ferro/metabolismo , Osteoblastos/metabolismo , Fosfatase Alcalina/metabolismo , Anemia Ferropriva/patologia , Apoptose/efeitos dos fármacos , Calcificação Fisiológica/efeitos dos fármacos , Linhagem Celular , Proliferação de Células/efeitos dos fármacos , Colágeno Tipo I/genética , Colágeno Tipo I/metabolismo , Desferroxamina/farmacologia , Suplementos Nutricionais/efeitos adversos , Compostos Férricos/efeitos adversos , Compostos Férricos/metabolismo , Regulação da Expressão Gênica/efeitos dos fármacos , Hormese , Humanos , Ferro/intoxicação , Deficiências de Ferro , Sobrecarga de Ferro/patologia , Osteoblastos/citologia , Osteoblastos/efeitos dos fármacos , Osteoblastos/patologia , Osteocalcina/genética , Osteocalcina/metabolismo , Osteogênese/efeitos dos fármacos , Compostos de Amônio Quaternário/efeitos adversos , Compostos de Amônio Quaternário/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Sideróforos/farmacologia
4.
J Asian Nat Prod Res ; 12(4): 265-72, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20419536

RESUMO

Transplantation of olfactory ensheathing cells (OECs) is currently considered to be one of the most promising repair strategies for human spinal cord injury. However, the factors that regulate OECs are still poorly understood. Ginsenoside Rg1 (Rg1), the phytosterol from Panax ginseng, is a potent neuroprotective agent that promotes axonal regeneration. The aim of this study is to determine whether Rg1 would influence the biological activity of OECs. Primary cultured OECs from the olfactory bulb of neonatal rats were treated with Rg1 of various concentrations and durations. Using MTT and bromodeoxyuridine assays, we found that Rg1 significantly promoted cell proliferation, with an optimal concentration of 40 mug/ml of Rg1 at 72 h. In addition, RT-PCR and ELISA assays showed that Rg1 could upregulate the mRNA expression and secretion of glial cell-derived neurotrophic factor, brain-derived neurotrophic factor, and nerve growth factor. These results suggest that Rg1 may have a great potential in OEC therapy.


Assuntos
Ginsenosídeos/farmacologia , Fatores de Crescimento Neural/efeitos dos fármacos , Regeneração Nervosa/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Condutos Olfatórios/citologia , Condutos Olfatórios/efeitos dos fármacos , Panax/química , Traumatismos da Medula Espinal/terapia , Animais , Sequência de Bases , Fator Neurotrófico Derivado do Encéfalo/efeitos dos fármacos , Fator Neurotrófico Derivado do Encéfalo/metabolismo , Ginsenosídeos/química , Ginsenosídeos/isolamento & purificação , Estrutura Molecular , Fatores de Crescimento Neural/metabolismo , Fármacos Neuroprotetores/química , Fármacos Neuroprotetores/isolamento & purificação , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA